EYS809

EYS809 is a first-in-class, nonviral gene therapy developed by Eyevensys for the sustained intraocular delivery of two therapeutic proteins—aflibercept (an anti–vascular endothelial growth factor [VEGF] protein) and decorin (an endogenous transforming growth factor-beta inhibitor with anti-fibrotic and anti-angiogenic properties). The therapy uses electrotransfection to deliver dual-gene plasmids into ciliary muscle cells, which then produce and secrete these proteins into the vitreous. This approach aims to reduce vascular leakage, choroidal neovascularization (CNV), and subretinal fibrosis in retinal diseases such as wet age-related macular degeneration (AMD), diabetic macular edema, macular dystrophy, and retinal vein occlusion. By providing sustained protein expression directly in ocular tissues without viral vectors or subretinal surgery, EYS809 seeks to decrease treatment burden compared to repeated intravitreal injections of current anti–VEGF therapies. Preclinical studies have shown that EYS809 outperforms standard aflibercept injections in reducing CNV lesions and promoting retinal pigment epithelium repopulation[1][4][5][6][7][8].

Other names

EYS809EYS-809EYS 809PST-809PST809PST 809